Home › Companies › LARIMAR THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and LARIMAR THERAPEUTICS INC.’s Form 8-K, filed 2025-05-13 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore LARIMAR THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are LARIMAR THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-13 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Thomas E. Hamilton | 46,479,322 | -- | -- | 4,326,129 | 6,865,481 | Majority: yes |
| Proposal 2 - Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2024. | 49,187,132 | 1,445,631 | 172,688 | -- | 6,865,481 | Majority: yes |
| Proposal 3 - Ratification of Independent Registered Public Accountant. | 57,657,322 | 10,851 | 2,759 | -- | 0 | Majority: yes |
Source: LARIMAR THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-05-13 — read the filing on EDGAR.
Each item below shows how the 110 asset managers that disclosed a LARIMAR THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
LARIMAR THERAPEUTICS INC.’s own tally for this item (“Proposal 2 - Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2024.”): 49,187,132 for, 1,445,631 against, per its Form 8-K filed 2025-05-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 64,027,892 outstanding shares: 77% for, 2% against (79% of the company cast a for/against vote).
The 108 asset managers below cast 98% of the shares they voted on this item FOR (48,533,636 for, 1,233,166 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. | 21,231,974 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 5,709,058 | 0 | 0 | 0 | For |
| Janus Henderson | 4,820,042 | 0 | 0 | 0 | For |
| Blue Owl Capital Holdings LP | 4,753,040 | 0 | 0 | 0 | For |
| BlackRock | 2,674,183 | 129 | 0 | 0 | For |
| Vanguard | 1,512,457 | 0 | 0 | 0 | For |
| Goldman Sachs | 930,630 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 0 | 850,631 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 765,092 | 0 | 0 | 0 | For |
| Fidelity | 693,374 | 0 | 0 | 0 | For |
| Woodline Partners LP | 622,682 | 0 | 0 | 0 | For |
| State Street | 621,982 | 181 | 0 | 0 | For |
| Opaleye Management Inc. | 550,000 | 0 | 0 | 0 | For |
| Citadel | 459,283 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 371,434 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 355,995 | 0 | 0 | 0 | For |
| Point72 | 254,384 | 0 | 0 | 0 | For |
| Northern Trust | 230,985 | 0 | 0 | 0 | For |
| Two Sigma | 204,565 | 0 | 0 | 0 | For |
| Charles Schwab | 200,914 | 0 | 0 | 0 | For |
| Nuveen | 174,788 | 0 | 0 | 0 | For |
| TIAA | 164,215 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 138,965 | 0 | 0 | 0 | For |
| UBS | 138,602 | 0 | 0 | 0 | For |
| American Century | 0 | 127,808 | 0 | 0 | Against |
Showing the 25 largest of 108 asset managers. See all 108 in the interactive database.
91% Majority: yes · of votes cast
LARIMAR THERAPEUTICS INC.’s own tally for this item (“Elect Director: Thomas E. Hamilton”): 46,479,322 for, 4,326,129 withheld, per its Form 8-K filed 2025-05-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 64,027,892 outstanding shares: 73% for, 7% withheld (79% of the company cast a for/withheld vote).
The 36 asset managers below cast 100% of the shares they voted on this item FOR (3,906,122 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,587,956 | 0 | 37,029 | 0 | For |
| Vanguard | 1,494,271 | 0 | 0 | 0 | For |
| Fidelity | 692,304 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 164,215 | 0 | Abstain |
| Charles Schwab | 0 | 0 | 100,457 | 0 | Abstain |
| BRIDGEWAY FUNDS INC | 0 | 0 | 96,916 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 70,068 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 63,904 | 0 | Abstain |
| Equitable | 23,314 | 0 | 33,060 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 48,282 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 31,200 | 0 | Abstain |
| ETFis Series Trust I | 0 | 0 | 26,869 | 0 | Abstain |
| Goldman Sachs | 0 | 0 | 26,037 | 0 | Abstain |
| Global X | 0 | 0 | 25,209 | 0 | Abstain |
| Northern Trust | 0 | 0 | 22,360 | 0 | Abstain |
| Dimensional | 0 | 0 | 21,565 | 0 | Abstain |
| Nationwide | 11,509 | 0 | 9,544 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 20,609 | 0 | Abstain |
| John Hancock | 0 | 0 | 16,157 | 0 | Abstain |
| State Street | 0 | 0 | 15,923 | 0 | Abstain |
| Pacific Life | 14,574 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 12,761 | 0 | Abstain |
| Voya | 0 | 0 | 12,092 | 0 | Abstain |
| Bridge Builder Trust | 8,134 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 6,900 | 0 | Abstain |
Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
LARIMAR THERAPEUTICS INC.’s own tally for this item (“Proposal 3 - Ratification of Independent Registered Public Accountant.”): 57,657,322 for, 10,851 against, per its Form 8-K filed 2025-05-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 64,027,892 outstanding shares: 90% for, 0.1% against (90% of the company cast a for/against vote).
The 36 asset managers below cast 100% of the shares they voted on this item FOR (4,732,573 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,624,985 | 0 | 0 | 0 | For |
| Vanguard | 1,494,271 | 0 | 0 | 0 | For |
| Fidelity | 692,304 | 0 | 0 | 0 | For |
| TIAA | 164,215 | 0 | 0 | 0 | For |
| Charles Schwab | 100,457 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 96,916 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 70,068 | 0 | 0 | 0 | For |
| American Century | 63,904 | 0 | 0 | 0 | For |
| Equitable | 56,374 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 48,282 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,200 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 26,869 | 0 | 0 | 0 | For |
| Goldman Sachs | 26,037 | 0 | 0 | 0 | For |
| Global X | 25,209 | 0 | 0 | 0 | For |
| Northern Trust | 22,360 | 0 | 0 | 0 | For |
| Dimensional | 21,565 | 0 | 0 | 0 | For |
| Nationwide | 21,053 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,609 | 0 | 0 | 0 | For |
| John Hancock | 16,157 | 0 | 0 | 0 | For |
| State Street | 15,923 | 0 | 0 | 0 | For |
| Pacific Life | 14,574 | 0 | 0 | 0 | For |
| ProShares | 12,761 | 0 | 0 | 0 | For |
| Voya | 12,092 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 8,134 | 0 | 0 | 0 | For |
| SEI | 6,900 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.
Ranked by the number of LARIMAR THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 64,027,892 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | DEERFIELD MANAGEMENT COMPANY, L.P. | 33.16% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 8.92% |
| 3 | Janus Henderson | 7.53% |
| 4 | Blue Owl Capital Holdings LP | 7.42% |
| 5 | BlackRock | 4.18% |
| 6 | Vanguard | 2.36% |
| 7 | Goldman Sachs | 1.45% |
| 8 | Alyeska Investment Group, L.P. | 1.33% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.19% |
| 10 | Fidelity | 1.08% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Deerfield Management Company, L.P. | 55.71% | 13D |
| Opaleye Management, Inc. | 6.42% | 13G |
| BlackRock | 4.88% | 13F |
| Goldman Sachs | 4.17% | 13F |
| Vanguard Group | 3.46% | 13F |
| Renaissance Technologies | 1.52% | 13F |
| Geode Capital | 1.42% | 13F |
| State Street | 1.30% | 13F |
| Millennium Management | 1.05% | 13F |
| Citadel Advisors | 0.78% | 13F |
Percentages above are of 64,027,892 shares outstanding, as reported by LARIMAR THERAPEUTICS INC. on its Form 10-Q dated 2025-04-27 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LARIMAR THERAPEUTICS INC.’s 10-Q dated 2025-04-27. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At LARIMAR THERAPEUTICS INC.'s shareholder meeting held 2025-05-13, in the 2024-2025 proxy season, 110 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 411 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS IN 2024 — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: LARIMAR THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-13.
LARIMAR THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.